Co-Development Agreement Sample Clauses

A Co-Development Agreement clause establishes the terms under which two or more parties collaborate to jointly develop a product, technology, or service. It typically outlines each party’s roles, responsibilities, contributions (such as funding, personnel, or intellectual property), and the process for decision-making and sharing results. This clause ensures that all parties have a clear understanding of their obligations and rights, helping to prevent disputes and facilitate smooth cooperation throughout the development process.
POPULAR SAMPLE Copied 14 times
Co-Development Agreement. For clarification, the selection of any program under the Co-Development Agreement shall not constitute the exercise of an Option in accordance with this Section 5, and, accordingly, no Option Exercise Fee will be payable and any paid Option Exercise Fee shall credited against any other payments by CureVac applied first to any outstanding payment obligations to Arcturus, and to the extent any remaining amounts remain creditable, then to the next due future payment obligations.
View SourceView Similar (2)
Co-Development Agreement. For clarification, the selection of any program under the Co-Development Agreement shall not constitute the delivery of an Acceptance Notice in accordance with this Section 5, and, accordingly, no Acceptance Fee will be payable and any paid Acceptance Fee shall be credited against any other payments by CureVac applied first to any outstanding payment obligations to Arcturus, and to the extent any remaining amounts remain creditable, then to the next due future payment obligations.”
View SourceView Similar (4)
Co-Development Agreement. If AZ designates a Potential Co-Development Antigen as a Co-Development Antigen pursuant to Section 2.2.1(l), the Parties shall negotiate in good faith to enter into a mutually acceptable written co-development and commercialization agreement (“Co-Development Agreement”) for the Exploitation of Antibody Equivalents that bind to and are directed against such Co-Development Antigen on a worldwide basis. The Co-Development Agreement shall provide (a) the sharing of the responsibility and control over the research, development and commercialization for such Antibody Equivalents by the Parties, (b) a mechanism, including the choice of legal vehicle, for the equal sharing of costs incurred in connection with the research and development of such Antibody Equivalents after such designation, and the equal sharing of profits and losses resulting from the commercialization of such Antibody Equivalents, (c) that ABX will have responsibility for the process development work for such Antibody Equivalents antibody products, and (d) such other commercially reasonable terms as the Parties may mutually agree.
View SourceView Similar (2)
Co-Development Agreement. For each Collaboration Lead Compound, the Parties will negotiate in good faith and finalize an agreement for the co-development of all associated Products (“Co-Development Agreement”), as soon as practicable following the [ * ]. The basis for the Co-Development Agreement shall be the terms and conditions contained in the Heads of Co-Development Agreement set forth in Appendix D [ * ]. Anything in this Agreement to the contrary notwithstanding, if the Parties do not execute a Co-Development Agreement for the relevant Product within [ * ]: (i) the [ * ] shall continue [ * ] the Parties; and (ii) the Parties shall [ * ].
View Source
Co-Development Agreement. This Warrant to Purchase Common Stock (“Warrant”) is issued in connection with the certain Co-Development Agreement dated as of January 9, 2020 by and between SFJ Pharmaceuticals X, Ltd. and the Company (as the same may from time to time be amended, modified, supplemented or restated) (the “Agreement”). THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SFJ PHARMACEUTICALS X, LTD. (together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and non-assessable shares (the “Shares”) of the above-stated common stock (the “Common Stock”) of PHASEBIO PHARMACEUTICALS, INC. (the “Company”) at the above-stated Warrant Price, which for the avoidance of doubt, shall be calculated in accordance with Section 8.1 of the Agreement (i.e., the per-share Warrant Price shall be equal to the greater of $5.00 or 120% of the volume weighted average closing price of the Company’s common stock over the thirty (30) consecutive trading days preceding the Effective Date, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant.
View Source
Co-Development Agreement. PDTC shall have executed and delivered to the Company the Co-Development Agreement for all photodynamic therapy applications of the Company's technology in the form of ANNEX C attached hereto.
View Source
Co-Development Agreement 
View Source

Related to Co-Development Agreement

  • Development Agreement As soon as reasonably practicable following the ISO’s selection of a transmission Short-Term Reliability Process Solution, the ISO shall tender to the Developer that proposed the selected transmission Short-Term Reliability Process Solution a draft Development Agreement, with draft appendices completed by the ISO to the extent practicable, for review and completion by the Developer. The draft Development Agreement shall be in the form of the ISO’s Commission-approved Development Agreement for its Reliability Planning Process, which is in Appendix C in Section 31.7 of Attachment Y of the ISO OATT, as amended by the ISO to reflect the Short-Term Reliability Process. The ISO and the Developer shall finalize the Development Agreement and appendices as soon as reasonably practicable after the ISO’s tendering of the draft Development Agreement. For purposes of finalizing the Development Agreement, the ISO and Developer shall develop the description and dates for the milestones necessary to develop and construct the selected project by the required in-service date identified in the STAR or Generator Deactivation Assessment, including the milestones for obtaining all necessary authorizations. Any milestone that requires action by a Connecting Transmission Owner or Affected System Operator identified pursuant to Attachment P of the ISO OATT to complete must be included as an Advisory Milestone, as that term is defined in the Development Agreement. If the ISO or the Developer determines that negotiations are at an impasse, the ISO may file the Development Agreement in unexecuted form with the Commission on its own, or following the Developer’s request in writing that the agreement be filed unexecuted. If the Development Agreement is executed by both parties, the ISO shall file the agreement with the Commission for its acceptance within ten (10) Business Days after the execution of the Development Agreement by both parties. If the Developer requests that the Development Agreement be filed unexecuted, the ISO shall file the agreement at the Commission within ten (10) Business Days of receipt of the request from the Developer. The ISO will draft, to the extent practicable, the portions of the Development Agreement and appendices that are in dispute and will provide an explanation to the Commission of any matters as to which the parties disagree. The Developer will provide in a separate filing any comments that it has on the unexecuted agreement, including any alternative positions it may have with respect to the disputed provisions. Upon the ISO’s and the Developer’s execution of the Development Agreement or the ISO’s filing of an unexecuted Development Agreement with the Commission, the ISO and the Developer shall perform their respective obligations in accordance with the terms of the Development Agreement that are not in dispute, subject to modification by the Commission. The Connecting Transmission Owner(s) and Affected System Operator(s) that are identified in Attachment P of the ISO OATT in connection with the selected transmission Short-Term Reliability Process Solution shall act in good faith in timely performing their obligations that are required for the Developer to satisfy its obligations under the Development Agreement.

  • Collaboration Agreement The Collaboration Agreement shall not have been terminated in accordance with its terms and shall be in full force and effect.

  • Cooperation Agreement At the Closing, PCC and Buyer shall, and PCC shall cause PCC Parent to, execute and deliver the Cooperation Agreement pursuant to which Buyer, PCC Parent and PCC shall provide each other certain information and other assistance in connection with the collection, administration and/or satisfaction of certain of the Retained Liabilities.

  • Design Development Documents See Section 2, Part 1, Article 2.1.5.

  • Staff Development As part of their induction, new staff will be made aware of this policy and will be asked to ensure compliance with its procedures at all times.